[go: up one dir, main page]

PE20081665A1 - Antagonistas del receptor de dopamina 2 de rapida disociacion - Google Patents

Antagonistas del receptor de dopamina 2 de rapida disociacion

Info

Publication number
PE20081665A1
PE20081665A1 PE2008000294A PE2008000294A PE20081665A1 PE 20081665 A1 PE20081665 A1 PE 20081665A1 PE 2008000294 A PE2008000294 A PE 2008000294A PE 2008000294 A PE2008000294 A PE 2008000294A PE 20081665 A1 PE20081665 A1 PE 20081665A1
Authority
PE
Peru
Prior art keywords
piperazin
dopamine
receptor antagonists
pyridazine
trifluoromethyl
Prior art date
Application number
PE2008000294A
Other languages
English (en)
Inventor
Jose Manuel Bartolome-Nebreda
Gregor James Mcdonald
Xavier Jean Michel Langlois
Gool Michiel Luc Maria Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38057298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20081665A1 publication Critical patent/PE20081665A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 4-ARIL-6-PIPERAZIN-1-IL-3-PIRIDAZINAS SUSTITUIDAS DE FORMULA (I) DONDE R1 ES CLORO, TRIFLUOROMETILO O CN; R2 ES FENILO, TIENILO, NAFTILO, INDOLILO, ENTRE OTROS; R3 ES H, ALQUILO(C1-C4), ALQUILOXI(C1-C4) O HALO; R4 Y R5 SON CADA UNO H O ALQUILO(C1-C4) O JUNTOS FORMAN ALCANODIILO(C1-C4); n ES 1 O 2; R6 ES H, ALQUILO(C1-C4), HIDROXIALQUILO(C2-C4), CICLOALQUILO(C3-C6), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-FENIL-6-PIPERAZIN-1-IL-3-TRIFLUOROMETIL-PIRIDAZINA, 4-(4-FLUOROFENIL)-6-PIPERAZIN-1-IL-3-TRIFLUOROMETIL-PIRIDAZINA, 4-FENIL-6-PIPERAZIN-1-IL-PIRIDAZINA-3-CARBONITRILO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE DOPAMINA 2 SIENDO UTILES EN EL TRATAMIENTO DE LA ESQUIZOFRENIA, ENFERMEDAD DE PARKINSON, ENFERMEDAD DE ALZHEIMER, TRASTORNO BIPOLAR
PE2008000294A 2007-02-13 2008-02-11 Antagonistas del receptor de dopamina 2 de rapida disociacion PE20081665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07102222 2007-02-13

Publications (1)

Publication Number Publication Date
PE20081665A1 true PE20081665A1 (es) 2008-11-22

Family

ID=38057298

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000294A PE20081665A1 (es) 2007-02-13 2008-02-11 Antagonistas del receptor de dopamina 2 de rapida disociacion

Country Status (31)

Country Link
US (2) US8791120B2 (es)
EP (1) EP2121630B1 (es)
JP (1) JP5225292B2 (es)
KR (1) KR101486408B1 (es)
CN (1) CN101605764B (es)
AR (1) AR065333A1 (es)
AU (1) AU2008214716B2 (es)
BR (1) BRPI0807492A2 (es)
CA (1) CA2674752C (es)
CL (1) CL2008000440A1 (es)
CY (1) CY1113759T1 (es)
DK (1) DK2121630T3 (es)
EA (1) EA017508B1 (es)
ES (1) ES2392470T3 (es)
HR (1) HRP20120876T1 (es)
IL (1) IL200310A (es)
JO (1) JO2849B1 (es)
MX (1) MX2009008616A (es)
MY (1) MY148899A (es)
NZ (1) NZ578560A (es)
PA (1) PA8768901A1 (es)
PE (1) PE20081665A1 (es)
PL (1) PL2121630T3 (es)
PT (1) PT2121630E (es)
RS (1) RS52515B (es)
SG (1) SG178779A1 (es)
SI (1) SI2121630T1 (es)
TW (1) TWI424847B (es)
UA (1) UA97826C2 (es)
UY (1) UY30910A1 (es)
WO (1) WO2008098892A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
DE102007007440A1 (de) 2007-02-15 2008-08-21 Bayerische Motoren Werke Aktiengesellschaft Verfahren zur Steuerung und/oder Regelung der Verdampfertemperatur einer Klimaanlage in einem Kraftfahrzeug
MX2009011415A (es) 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
CA2682671C (en) * 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
AU2008240727C1 (en) * 2007-04-23 2013-10-03 Janssen Pharmaceutica N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
EP2310374B1 (en) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EA019048B1 (ru) 2008-07-31 2013-12-30 Янссен Фармацевтика Нв Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина
US8431575B2 (en) 2010-02-18 2013-04-30 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933823A (en) * 1971-03-29 1976-01-20 E. R. Squibb & Sons, Inc. Isoxazolopyridine ketone derivatives
DE2341965C3 (de) * 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
NO147672C (no) 1975-09-23 1983-05-25 Janssen Pharmaceutica Nv Analogifremgangsmaate for fremstilling av n-aryl-n-(1-l1-4-piperidinyl)-arylacetamider
EG12406A (en) * 1976-08-12 1979-03-31 Janssen Pharmaceutica Nv Process for preparing of novel n-aryl-n-(1-l-4-piperidinyl)-arylacetamides
DE3218482A1 (de) * 1982-05-15 1983-11-17 Bayer Ag, 5090 Leverkusen Substituierte 5-trifluormethyl-1,3,4-thiadiazol-2-yloxyessigsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als herbizide
ES8802151A1 (es) 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Un procedimiento para la preparacion de nuevos piridazinaminas.
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
PT93060B (pt) 1989-02-07 1995-12-29 Sanofi Sa Processo para a obtencao de derivados de piridazina e de composicoes farmaceuticas que os contem
US5461053A (en) * 1989-02-07 1995-10-24 Sanofi Pyridazine derivatives
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
WO1995018118A1 (en) 1993-12-28 1995-07-06 The Upjohn Company Heterocyclic compounds for the treatment of cns and cardiovascular disorders
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
TW406075B (en) 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5753679A (en) 1995-05-10 1998-05-19 Hoffmann-La Roche Inc. Benzyl-piperidine derivatives
MY116093A (en) * 1996-02-26 2003-11-28 Upjohn Co Azolyl piperazinyl phenyl oxazolidinone antimicrobials
TW504510B (en) 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
AU8457298A (en) * 1997-08-15 1999-03-08 Pfizer Products Inc. 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives interacting with the dopamine D4 receptor
KR100261139B1 (ko) 1998-01-16 2000-08-01 황준수 신규한 알릴티오피리다진 유도체 및 그의 제조방법
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
ES2261658T3 (es) 2001-02-23 2006-11-16 MERCK & CO., INC. Antagonistas nmda/nr2b heterociclicos no arilicos n-sustituidos.
CA2468529C (en) 2001-10-09 2011-03-01 Kyorin Pharmaceutical Co., Ltd. 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
AU2002360561A1 (en) 2001-12-11 2003-06-23 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
WO2003062215A1 (en) 2002-01-25 2003-07-31 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
CA2474214A1 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
BR0307902A (pt) 2002-02-22 2004-12-21 Upjohn Co Derivados de piridil sulfona como antagonistas de receptor 5-ht
SE0201544D0 (sv) 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
ATE551053T1 (de) * 2002-09-26 2012-04-15 Mandom Corp Antiseptische bakterizide, und kosmetika, arzneimittel und lebensmittel, die die antiseptischen bakterizide enthalten
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CN100469769C (zh) 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
BR0318298A (pt) * 2003-05-07 2006-07-11 Ifac Gmbh & Co Kg composições para a liberação dirigida de fragráncias e aromas
BRPI0410239A (pt) 2003-05-08 2006-05-16 Kyorin Seiyaku Kk composto de 4-(2-furoil)aminopiperidina e medicamento
WO2005005779A2 (en) 2003-07-14 2005-01-20 Genesis Mining Technologies (Pty) Ltd Dual retention cutting arrangement
DK1651615T3 (da) 2003-07-29 2010-05-25 High Point Pharmaceuticals Llc Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
US7335658B2 (en) 2003-07-30 2008-02-26 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
WO2005046581A2 (en) 2003-10-24 2005-05-26 Cheng Tao M D P18 in stem cell manipulations
JP2007522224A (ja) 2004-02-10 2007-08-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ α4インテグリン拮抗薬としてのピリダジノン尿素
WO2005090317A1 (en) 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
EP1742932A1 (en) 2004-04-28 2007-01-17 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
RU2006146985A (ru) * 2004-05-28 2008-07-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы мускариновых рецепторов
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
AR052319A1 (es) 2004-10-29 2007-03-14 Kalypsys Inc Compuestos biciclicos sustituidos por sulfonilo en funcion de moduladores del ppar
EP2279756A2 (en) * 2005-04-05 2011-02-02 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Method for shielding functional sites or epitopes on proteins
EP1902046B1 (en) 2005-06-20 2009-12-02 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
JP2010500391A (ja) 2006-08-15 2010-01-07 エフ.ホフマン−ラ ロシュ アーゲー フェニル、ピリジン及びキノリン誘導体
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
JO2642B1 (en) * 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
MX2009011415A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Derivados de 4-alcoxipiridazina como antagonistas del receptor de dopamina 2 de rapida disociacion.
AU2008240727C1 (en) * 2007-04-23 2013-10-03 Janssen Pharmaceutica N.V. Pyridine derivatives as fast dissociating dopamine 2 receptor antagonists
CA2682671C (en) * 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
US8299257B2 (en) * 2007-09-20 2012-10-30 Glaxo Group Limited Compounds which have activity at M1receptor and their uses in medicine
EP2310374B1 (en) * 2008-07-03 2012-10-31 Janssen Pharmaceutica N.V. Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
EA019048B1 (ru) * 2008-07-31 2013-12-30 Янссен Фармацевтика Нв Пиперазин-1-илтрифторметилзамещенные пиридины в качестве быстро диссоциирующихся антагонистов d-рецепторов дофамина

Also Published As

Publication number Publication date
JP2010518051A (ja) 2010-05-27
US20140336381A1 (en) 2014-11-13
KR20090129402A (ko) 2009-12-16
EA017508B1 (ru) 2013-01-30
PA8768901A1 (es) 2008-11-19
TW200902006A (en) 2009-01-16
EP2121630B1 (en) 2012-08-01
PT2121630E (pt) 2012-11-02
SG178779A1 (en) 2012-03-29
US9422296B2 (en) 2016-08-23
BRPI0807492A2 (pt) 2014-05-27
PL2121630T3 (pl) 2012-12-31
SI2121630T1 (sl) 2012-12-31
RS52515B (sr) 2013-04-30
HRP20120876T1 (hr) 2012-11-30
EP2121630A1 (en) 2009-11-25
AR065333A1 (es) 2009-06-03
EA200970760A1 (ru) 2009-12-30
US20100069394A1 (en) 2010-03-18
WO2008098892A1 (en) 2008-08-21
JO2849B1 (en) 2015-03-15
ES2392470T3 (es) 2012-12-11
AU2008214716B2 (en) 2013-05-09
CN101605764A (zh) 2009-12-16
KR101486408B1 (ko) 2015-01-27
MX2009008616A (es) 2009-08-20
IL200310A (en) 2013-07-31
CN101605764B (zh) 2013-06-19
UA97826C2 (ru) 2012-03-26
TWI424847B (zh) 2014-02-01
DK2121630T3 (da) 2012-11-12
UY30910A1 (es) 2008-09-02
IL200310A0 (en) 2010-04-29
NZ578560A (en) 2010-12-24
JP5225292B2 (ja) 2013-07-03
CL2008000440A1 (es) 2008-08-22
MY148899A (en) 2013-06-14
CA2674752A1 (en) 2008-08-21
CA2674752C (en) 2015-03-31
US8791120B2 (en) 2014-07-29
CY1113759T1 (el) 2016-07-27
AU2008214716A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20141375A1 (es) Activadores de glucoquinasa
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20140934A1 (es) Derivados de pirazol
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20110852A1 (es) Antagonistas del receptor de orexina de isonicotinamida
PE20090592A1 (es) Nuevos derivados de piperazina-amida
PE20090651A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
PE20081876A1 (es) Aminoamidas como antagonistas de orexina
PE20120063A1 (es) Derivados de ciclopropilamida dirigidos contra el receptor de histamina h3
PE20081152A1 (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3
PE20090591A1 (es) Derivados monoamida como antagonistas del receptor de orexina
PE20120640A1 (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)

Legal Events

Date Code Title Description
FG Grant, registration